Organization
Hospital Universitario Puerta de Hierro-Majadahonda
13 abstracts
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.Org: Dana-Farber Cancer Institute, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Bristol Myers Squibb, Institut Curie, Saint Cloud, France, McGill University Health Center,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.Org: Hospital Clínic Barcelona, Antwerp University Hospital, Hospital Univ. Miguel Servet, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Complejo Hospitalario Universitario Ourense,
Abstract
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.Org: Hospital Universitario Puerta de Hierro-Majadahonda, Hospital Universitario A Coruña, Son Espases University Hospital, Hospital Regional Carlos Haya, Catalan Institute of Oncology-Hospitalet,
Abstract
Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy.Org: Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana, Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, H Puerta De Hierro (Spain), Madrid, Spain,
Abstract
The CLARIFY digital decision support platform: An artificial intelligence tool for exploring multidimensional cancer data.Org: Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Politecnica de Madrid, Universidad NOVA De Lisboa, Puerta de Hierro Majadahonda University Hospital,
Abstract
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.Org: Hospital Universitario San Pedro de Alcántara, Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitari Vall d’Hebron y Vall Hebrón Institute of Oncology (VHIO),
Abstract
Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).Org: Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto Investigacion Sanitaria Puerta de Hierro-Segovia de Arana, Fundación para la Investigación Biomédica Hospital Universitario Puerta de Hierro, C/ Joaquín Rodrigo, 1, 28222 Majadahonda,
Abstract
Cost savings and clinical outcomes in cancer patients enrolled in clinical trials from a national public health system perspective.Org: MD Anderson Cancer Center Madrid, Hospital Universitario de Ramon y Cajal, Madrid, Spain, Ramón y Cajal University Hospital, Medical Oncology Group, Internal Medicine Department VI,
Abstract
ACCURACY OF PHYSICAL EXAMINATION IN THE EVALUATION OF ROTATOR CUFF LESIONS DIAGNOSED BY MRIOrg: Rheumatology Department, Imaging Department, Biostatistics Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain,